Premium
Survival outcomes and treatment costs for patients with double‐refractory chronic lymphocytic leukaemia ( DR ‐ CLL )
Author(s) -
Bloor Adrian,
De Cock Erwin,
Hatswell Anthony J,
Wasiak Radek,
Elvidge Jamie,
Stapelkamp Ceilidh,
Hadjivassileva Tsveta,
Haiderali Amin,
Delgado Julio
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13224
Subject(s) - alemtuzumab , medicine , fludarabine , population , chronic lymphocytic leukemia , refractory (planetary science) , pediatrics , oncology , leukemia , chemotherapy , transplantation , environmental health , physics , astrobiology , cyclophosphamide
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom